N‐terminal pro‐B‐type natriuretic peptide and high‐sensitivity troponin T hold diagnostic value in cardiac amyloidosis
暂无分享,去创建一个
M. Emdin | P. Hawkins | D. Logeart | C. Passino | M. Fontana | A. Giannoni | A. Wechalekar | H. Lachmann | J. Gillmore | A. Clerico | C. Prontera | G. Georgiopoulos | A. Aimo | G. Buda | G. Vergaro | A. Cohen Solal | V. Chubuchny | V. Castiglione | S. Masotti | Y. Razvi | V. Musetti | M. Nicol | Alberto Aimo | Giuseppe Vergaro | R. Patel | Alberto Giannoni | Claudio Passino | Michele Emdin | Kiara N Patel | Aldo Clerico | Vincenzo Castiglione | Concetta Prontera | Silvia Masotti | Veronica Musetti | Martin Nicol | Alain Cohen Solal | Damien Logeart | Georgios Georgiopoulos | Vladyslav Chubuchny | Gabriele Buda | Yousuf Razvi | Rishi Patel | Ashutosh Wechalekar | Helen Lachmann | Philip N. Hawkins | Julian Gillmore
[1] M. Emdin,et al. Critical Comparison of Documents From Scientific Societies on Cardiac Amyloidosis: JACC State-of-the-Art Review. , 2022, Journal of the American College of Cardiology.
[2] M. Emdin,et al. Biomarkers for the diagnosis and management of heart failure , 2021, Heart Failure Reviews.
[3] U. Eriksson,et al. Diagnosis and treatment of cardiac amyloidosis: a position statement of the ESC Working Group on Myocardial and Pericardial Diseases. , 2021, European heart journal.
[4] M. Emdin,et al. Use of biomarkers to diagnose and manage cardiac amyloidosis , 2021, European journal of heart failure.
[5] M. Emdin,et al. A simple echocardiographic score to rule out cardiac amyloidosis , 2020, European journal of clinical investigation.
[6] Deepak L. Bhatt,et al. 2020 ESC Guidelines for the management of acute coronary syndromes in patients presenting without persistent ST-segment elevation. , 2020, European heart journal.
[7] M. Emdin,et al. Keys to early diagnosis of cardiac amyloidosis: red flags from clinical, laboratory and imaging findings , 2020, European journal of preventive cardiology.
[8] A. Cohen-Solal,et al. Diagnostic score of cardiac involvement in AL amyloidosis. , 2020, European heart journal cardiovascular Imaging.
[9] G. Pontone,et al. Multiparametric Echocardiography Scores for the Diagnosis of Cardiac Amyloidosis. , 2019, JACC. Cardiovascular imaging.
[10] C. Rapezzi,et al. Expert Consensus Recommendations for the Suspicion and Diagnosis of Transthyretin Cardiac Amyloidosis. , 2019, Circulation. Heart failure.
[11] M. Plebani,et al. Evaluation of reproducibility of the cTnT immunoassay using quality control samples. , 2019, Clinica chimica acta; international journal of clinical chemistry.
[12] M. Woodward,et al. Comparison between High-Sensitivity Cardiac Troponin T and Cardiac Troponin I in a Large General Population Cohort. , 2018, Clinical chemistry.
[13] Y. Izumiya,et al. Diagnostic utility of cardiac troponin T level in patients with cardiac amyloidosis , 2017, ESC heart failure.
[14] A. Dispenzieri,et al. Light-chain cardiac amyloidosis: strategies to promote early diagnosis and cardiac response , 2017, Heart.
[15] James C Moon,et al. Nonbiopsy Diagnosis of Cardiac Transthyretin Amyloidosis , 2016, Circulation.
[16] Victor Mor-Avi,et al. Recommendations for cardiac chamber quantification by echocardiography in adults: an update from the American Society of Echocardiography and the European Association of Cardiovascular Imaging. , 2015, European heart journal cardiovascular Imaging.
[17] J. Deux,et al. Role of natriuretic peptide to predict cardiac abnormalities in patients with hereditary transthyretin amyloidosis , 2013, Amyloid : the international journal of experimental and clinical investigation : the official journal of the International Society of Amyloidosis.
[18] A. Foli,et al. Best use of cardiac biomarkers in patients with AL amyloidosis and renal failure , 2012, American journal of hematology.
[19] M. Emdin,et al. Comparison between analytical performances of polyclonal and monoclonal electrochemiluminescence immunoassays for NT-proBNP. , 2009, Clinica chimica acta; international journal of clinical chemistry.
[20] R. Falk,et al. Definition of organ involvement and treatment response in immunoglobulin light chain amyloidosis (AL): A consensus opinion from the 10th International Symposium on Amyloid and Amyloidosis , 2005, American journal of hematology.
[21] A. Balduini,et al. Serum N-Terminal Pro–Brain Natriuretic Peptide Is a Sensitive Marker of Myocardial Dysfunction in AL Amyloidosis , 2003, Circulation.
[22] N. Reichek,et al. Echocardiographic assessment of left ventricular hypertrophy: comparison to necropsy findings. , 1986, The American journal of cardiology.